CHIC Project Survey: Your Opinion Counts

The EU-funded CHIC project (Computational Horizons In Cancer: Developing Meta- and Hyper-Multiscale Models and Repositories for In Silico Oncology) proposes the development of clinical trial driven tools, services and secure infrastructure that will support the creation of multiscale cancer hypermodels (integrative models). The latter are defined as choreographies of component models, each one describing a biological process at a characteristic spatiotemporal scale, and of relation models/metamodels defining the relations across scales. Integrative models can become component models for other integrative models. The development of a secure hypermodelling infrastructure consisting primarily of a hypermodelling editor and a hypermodelling execution environment is a central generic VPH geared objective of CHIC.

To understand the views, opinions and expectations of citizens and patients about the cancer models/hypermodels a short survey was developed, it will help to optimize research in this area. A short survey video will present the hypermodel developed for nephroblastoma, the most common kidney cancer in children. It will answer the question if preoperative chemotherapy will shrink the tumor before surgery. The prediction of this hypermodel may then be used for helping the physician to apply the best treatment for a patient with nephroblastoma.

The survey video is followed by a short questionnaire consisting of two main parts. The first part is asking demographic questions and the second part is related to the understanding of hypermodels. Your answers are anonymous and the whole survey will take you less than 10 minutes.

You are kindly invited to participate in the hypermodel survey of CHIC project. This survey will help CHIC project consortium to understand the knowledge, expectations and opinions of citizens and patients about the cancer models/hypermodels.

For further information, survey video and survey questions, please visit:
http://www.ehealthserver.com/survey/index.php?r=survey/index&sid=423562

For further information about CHIC project, please visit:
http://www.chic-vph.eu

CHIC project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement No 600841.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...